A pilot proof of concept study of the Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders (EASi-RAIR)

Brief description of study

The purpose of this research is to study Short Chain Fatty Acids (SCFAs), bacterial fermentation products that are naturally found at varying concentrations in your gut, and how it affects the abundance of microorganisms in your gut, as well as T regulatory cells in your blood. SCFAs are metabolites that are known to change the immune response in animal models of inflammation. This study is important because we hypothesize that changes in the gut microbiome and the regulatory immune response may improve treatment of rheumatoid arthritis (RA).

SCFAs are not an FDA-approved treatment for RA or for any other condition. We are not studying SCFAs as a treatment for your condition. We only want to see the effect of SCFAs on the microorganisms in your gut and on certain blood measures.

Clinical Study Identifier: s22-01526
Principal Investigator: Jose U Scher.
Other Investigator: Rebecca Barbara Blank.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.